Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure 1 Diagram showing analysis flow of patient selection and treatment allocation of ONTARGET/TRANSCEND. Figure 1 Diagram showing analysis flow of patient.

Published byRalph Wood Modified over 5 years ago

Similar presentations

Presentation on theme: "Figure 1 Diagram showing analysis flow of patient selection and treatment allocation of ONTARGET/TRANSCEND. Figure 1 Diagram showing analysis flow of patient."— Presentation transcript:

1 Figure 1 Diagram showing analysis flow of patient selection and treatment allocation of ONTARGET/TRANSCEND. Figure 1 Diagram showing analysis flow of patient selection and treatment allocation of ONTARGET/TRANSCEND. Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) For permissions, please article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model ( Eur Heart J, ehz149, The content of this slide may be subject to copyright: please see the slide notes for details.

2 Figure 2 Distribution of mean achieved systolic blood pressure (A) and mean achieved diastolic blood pressure (B) in ... Figure 2 Distribution of mean achieved systolic blood pressure (A) and mean achieved diastolic blood pressure (B) in patients with diabetes (red) or no diabetes (blue). Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) For permissions, please article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model ( Eur Heart J, ehz149, The content of this slide may be subject to copyright: please see the slide notes for details.

3 Figure 3 Cumulative incidence curves for the primary outcome (A), cardiovascular death (B), myocardial infarction (C), ... Figure 3 Cumulative incidence curves for the primary outcome (A), cardiovascular death (B), myocardial infarction (C), stroke (D), hospitalization for congestive heart failure (E), and all-cause death (F) according to mean achieved systolic blood pressure groups (<120 mmHg, 120 to <140 mmHg, 140 to <160 mmHg, and ≥160 mmHg). The primary outcome includes cardiovascular death, myocardial infarction, stroke, and hospitalization for heart failure. Solid lines depict diabetes and dotted lines no diabetes. Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) For permissions, please article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model ( Eur Heart J, ehz149, The content of this slide may be subject to copyright: please see the slide notes for details.

4 Figure 4 Hazard ratios (left) and yearly event rates (right) for mean achieved systolic (SBP) (left) and mean achieved ... Figure 4 Hazard ratios (left) and yearly event rates (right) for mean achieved systolic (SBP) (left) and mean achieved diastolic (DBP) (right) blood pressure in diabetes (red, above) and no diabetes (blue, below) for the primary outcome (A), cardiovascular death (B), myocardial infarction (C), stroke (D), hospitalization for congestive heart failure (E), and all-cause death (F). The primary outcome includes cardiovascular death, myocardial infarction, stroke, and hospitalization for heart failure. The hazard ratios (Cox regression) were adjusted for the variables diastolic blood pressure (for systolic blood pressure), systolic blood pressure (for achieved diastolic blood pressure), heart rate, age, sex, body mass index, renal function, geographical region, physical activity, formal education, alcohol consumption, tobacco use, history of hypertension, myocardial infarction, stroke/transient ischaemic attack, heart rhythm, co-medications, study and study medications. Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) For permissions, please article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model ( Eur Heart J, ehz149, The content of this slide may be subject to copyright: please see the slide notes for details.

5 Figure 5 Hazard ratio according to mean achieved systolic blood pressure for the adjusted hazard ratios for primary ... Figure 5 Hazard ratio according to mean achieved systolic blood pressure for the adjusted hazard ratios for primary outcome (A), cardiovascular death (B), myocardial infarction (C), stroke (D), hospitalization for congestive heart failure (E), and all-cause death (F). The analyses were adjusted for the same variables as described in Figure 4. The reference (hazard ratio = 1) is mean in-trial systolic blood pressure of 140 mmHg in patients without diabetes. Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) For permissions, please article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model ( Eur Heart J, ehz149, The content of this slide may be subject to copyright: please see the slide notes for details.

6 Figure 6 Hazard ratio according to mean achieved diastolic blood pressure for the adjusted hazard ratios for primary ... Figure 6 Hazard ratio according to mean achieved diastolic blood pressure for the adjusted hazard ratios for primary outcome (A), cardiovascular death (B), myocardial infarction (C), stroke (D), hospitalization for congestive heart failure (E), and all-cause death (F). The analyses were adjusted for the same variables as described in Figure 4. The reference (hazard ratio = 1) is mean in-trial diastolic blood pressure of 80 mmHg in patients without diabetes. Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) For permissions, please article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model ( Eur Heart J, ehz149, The content of this slide may be subject to copyright: please see the slide notes for details.

7 Take home figure Systolic blood pressure is shifted to a higher average level in patients with diabetes (A, left). ... Take home figure Systolic blood pressure is shifted to a higher average level in patients with diabetes (A, left). Cardiovascular risk in diabetic patients is further augmented by autonomic neuropathy and dysbalance, lipid disorder, RAGE and AGE modifications, higher heart rates, comorbidities such as coronary artery disease, heart failure, renal failure, arrhythmias, and others (A, right). This leads to higher event rates and increased hazards for cardiovascular death, myocardial infarction, stroke, hospitalized congestive heart failure, and all-cause death (B), which is independent of levels of in-trial blood pressure for all outcomes (C). Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) For permissions, please article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model ( Eur Heart J, ehz149, The content of this slide may be subject to copyright: please see the slide notes for details.

Download ppt "Figure 1 Diagram showing analysis flow of patient selection and treatment allocation of ONTARGET/TRANSCEND. Figure 1 Diagram showing analysis flow of patient."

Similar presentations

Copyright © 2007 American Medical Association. All rights reserved.

Copyright © 2007 American Medical Association. All rights reserved.
Figure 1 Patient selection flow chart

Figure 1 Patient selection flow chart
Figure 1 Rates of complications and mortality during index admission for atrial fibrillation ablation for the overall ... Figure 1 Rates of complications.

Figure 1 Rates of complications and mortality during index admission for atrial fibrillation ablation for the overall ... Figure 1 Rates of complications.
Figure 1 Periprocedural myonecrosis and myocardial infarction after left main coronary artery revascularization with ... Figure 1 Periprocedural myonecrosis.

Figure 1 Periprocedural myonecrosis and myocardial infarction after left main coronary artery revascularization with ... Figure 1 Periprocedural myonecrosis.
Figure 1 Subject phenotypes and most common genotype in subjects enrolled in THAOS in continental Western Europe. Data ... Figure 1 Subject phenotypes.

Figure 1 Subject phenotypes and most common genotype in subjects enrolled in THAOS in continental Western Europe. Data ... Figure 1 Subject phenotypes.
Figure 1 Study flow diagram and definition of clinical response

Figure 1 Study flow diagram and definition of clinical response
Figure 1 Overall lag-cumulative exposure–response relationships between air temperature and myocardial infarction ... Figure 1 Overall lag-cumulative exposure–response.

Figure 1 Overall lag-cumulative exposure–response relationships between air temperature and myocardial infarction ... Figure 1 Overall lag-cumulative exposure–response.
Unless provided in the caption above, the following copyright applies to the content of this slide: © 2019 European Society of Cardiology and British Pharmacological.

Unless provided in the caption above, the following copyright applies to the content of this slide: © 2019 European Society of Cardiology and British Pharmacological.
Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.
Figure 1 Data-selection process

Figure 1 Data-selection process
Figure 1 Flow diagram detailing the systematic review process.

Figure 1 Flow diagram detailing the systematic review process.
Figure 1 Multivariable-adjusted predictors of PAC

Figure 1 Multivariable-adjusted predictors of PAC
Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.
Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.
Figure 1 Unadjusted Kaplan–Meier curves for all-cause mortality in the transcatheter mitral valve repair and ... Figure 1 Unadjusted Kaplan–Meier curves.

Figure 1 Unadjusted Kaplan–Meier curves for all-cause mortality in the transcatheter mitral valve repair and ... Figure 1 Unadjusted Kaplan–Meier curves.
Figure 1 Mechanism of mortality benefit associated with radial access

Figure 1 Mechanism of mortality benefit associated with radial access
(A) mSchober in DESIR; (B) mSchober in SPACE; (C) LSF ...

(A) mSchober in DESIR; (B) mSchober in SPACE; (C) LSF ...
Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.
Figure 1 Number of percutaneous coronary interventions (PCI) in mainland China, 2017 (total 753 142). Data from China ... Figure 1 Number of percutaneous.

Figure 1 Number of percutaneous coronary interventions (PCI) in mainland China, 2017 (total 753 142). Data from China ... Figure 1 Number of percutaneous.
Figure 1. Multivariable-adjusted hazard ratios (solid line) for incident chronic obstructive pulmonary disease as a ... Figure 1. Multivariable-adjusted.

Figure 1. Multivariable-adjusted hazard ratios (solid line) for incident chronic obstructive pulmonary disease as a ... Figure 1. Multivariable-adjusted.

Similar presentations

Ads by Google